Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| PRO-118 |
Not provided
Not provided
Reformulation
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of four doses of PRO-118 ophthalmic solution ophthalmic solution compared with placebo, for the treatment of seasonal (SAC) and perennial (PAC) allergic conjunctivitis.
A phase II, double-masked, randomized, placebo-controlled, parallel-group and multicenter clinical trial, to evaluate and compared the clinical efficacy and safety of four doses of PRO-118 ophthalmic solution ( PRO-118 0.015% qd, PRO-118 0.015% twice daily , PRO-118 0.020% qd, PRO-118 0.020% twice daily) for the treatment of seasonal (SAC) and perennial (PAC) allergic conjunctivitis.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm A. PRO-118/Placebo 0.015%,0.020% | Experimental |
| |
| Arm B. PRO-118/Placebo 0.015%,0.020% | Experimental |
| |
| Arm C. PRO-118/Placebo 0.015%,0.020% | Experimental |
| |
| Arm D. PRO-118/Placebo 0.015%,0.020% | Experimental |
| |
| Arm E PRO-118/Placebo 0.015%,0.020% | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PRO-118 Ophthalmic Solution 0.015% | Drug | PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy of PRO-118 ophthalmic solution. | Primary efficacy measure: Evaluation of ocular itching. Secondary efficacy measures: Evaluation of symptoms(redness eye,ocular irritation, foreign body sensation, photophobia and lacrimation) and signs(conjunctival hyperaemia,chemosis, mucous discharge ocular and presence of follicles/papillae). | 21 days. |
| Measure | Description | Time Frame |
|---|---|---|
| Safety of PRO-118 Ophthalmic Solution. |
| 21 days. |
Not provided
Inclusion Criteria:
Applicable in patients ≥ 18 years old.
Applicable in patients with age ≤ 18 years old.
Exclusion Criteria:
Discontinuation criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| MarÃa C Jiménez-MartÃnez, MD | "Instituto de OftalmologÃa Fundación Conde de Valenciana, I.A.P." | Principal Investigator |
| Concepción Santacruz-Valdés, MD | "Instituto de OftalmologÃa Fundación Conde de Valenciana, I.A.P." | Principal Investigator |
| Emma T Villaseñor-Fierro, MD | Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde" | Principal Investigator |
| Miriam Becerra-Cotta, MD | Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde" | Principal Investigator |
| Leopoldo M Baiza-Durán, MD | Clinical Research Department. Laboratorios Sophia SA de CV | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde" | Guadalajara | Jalisco | 44280 | Mexico | ||
| "Instituto de OftalmologÃa Fundación Conde de Valenciana, I.A.P |
Not provided
Not provided
Not provided
Not provided
Not provided
| PRO-118 Ophthalmic Solution 0.015 % | Drug | PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days |
|
| PRO-118 Ophthalmic Solution 0.020 % | Drug | PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days |
|
| PRO-118 Ophthalmic Solution 0.020 % | Drug | PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days |
|
| Placebo Ophthalmic Solution | Drug | Placebo Ophthalmic Solution applied qd during 21 days |
|
| Mexico City |
| 06800 |
| Mexico |
| ID | Term |
|---|---|
| D003233 | Conjunctivitis, Allergic |
| ID | Term |
|---|---|
| D003231 | Conjunctivitis |
| D003229 | Conjunctival Diseases |
| D005128 | Eye Diseases |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
Not provided
Not provided